[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
[2] Böckmann L, Jedinger S, Kirschey T. Vierte regionalisierte Bevölkerungs-vorausberechnung [4th regionalised population forecast]. Office of Statistics Rhineland-Palatine. 2015. https://www.statistik.rlp.de/dokumente/stat_analysen/ rp2060_bj2013. Accessed 17 Oct 2019.
[3] Robert-Koch-Institut. Krebs in Deutschland 2011/2012 [Cancer in Germany 2011/2012]. Robert-Koch-Institut. 2015. https://www.krebsdaten.de/Content/ Krebs_in_Deutschland/kid_2015. Accessed 17 Oct 2019.
[4] Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006;42:1671–83.
[5] Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88:226–35.
[6] Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019;37:1228-63.
[7] Palumbo A, Anderson KC. Multiple myeloma. N Engl J Med. 2011;364: 1046-60.
[8] Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, Møller H; Consultant Haematologists, South Thames Haematology Specialist Committee. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol. 2004;127:299–304.
[9] Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009;83:139-48.
[10] Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A, Petrucci MT. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27:1959-69.
[11] Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology. 2011;20:88-97.
[12] Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Living with multiple myeloma: Experiences of patients and their informal caregivers. Support Care Cancer. 2011;19:101-11.
[13] Maher K, de Vries K. An exploration of the lived experiences of individuals with relapsed multiple myeloma. Eur J Cancer Care (Engl). 2011;20:267-75.
[14] Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97:416-429.
[15] Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2016;34:557-65.
[16] Etkind SN, Daveson BA, Kwok W, Witt J, Bausewein C, Higginson IJ, Murtagh FE. Capture, transfer, and feedback of patient-centered outcomes data in palliative care populations: does it make a difference? A systematic review. J Pain Symptom Manage. 2015;49:611-24.
[17] Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol. 2012;89:437-57.
[18] Wagner LI, Robinson D, Weiss M, Katz M, Greipp PR, Fonseca R, Cella D. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage. 2012;43:1094-104.
[19] Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J; EORTC Quality of Life Group. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43:1670-8.
[20] Jones D1, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol. 2013;6:13.
[21] Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, Davies FE. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes. 2014;12:35.
[22] Osborne TR, Ramsenthaler C, Schey SA, Siegert RJ, Edmonds PM, Higginson IJ. Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS). BMC Cancer. 2015;15:280.
[23] Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Qual Health Care. 1998;8:219-27.
[24] Murtagh FE, Ramsenthaler C, Firth A, Groeneveld EI, Lovell N, Simon ST, Denzel J, Guo P, Bernhardt F, Schildmann E, van Oorschot B, Hodiamont F, Streitwieser S, Higginson IJ, Bausewein C. A brief, patient- and proxy-reported outcome measure in advanced illness: Validity, reliability and responsiveness of the Integrated Palliative care Outcome Scale (IPOS). Palliat Med. 2019;33:1045-57.
[25] Schildmann EK, Groeneveld EI, Denzel J, Brown A, Bernhardt F, Bailey K, Guo P, Ramsenthaler C, Lovell N, Higginson IJ, Bausewein C, Murtagh FE. Discovering the hidden benefits of cognitive interviewing in two languages: The first phase of a validation study of the Integrated Palliative care Outcome Scale. Palliat Med. 2016;30:599-610.
[26] Ramsenthaler C, Gao W, Siegert RJ, Schey SA, Edmonds PM, Higginson IJ. Longitudinal validity and reliability of the Myeloma Patient Outcome Scale (MyPOS) was established using traditional, generalizability and Rasch psychometric methods. Qual Life Res. 2017;26:2931-47.
[27] Davies JM, Osborne TR, Edmonds PM, Schey SA, Devereux S, Higginson IJ, Ramsenthaler C. The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma. Eur J Haematol. 2017;98:508-16.
[28] Warnecke RB, Johnson TP, Chavez N, Sudman S, O'Rourke DP, Lacey L, Horm J. Improving Question Wording in Surveys of Culturally Diverse Populations. Ann Epidemiol. 1997;7:334–42.
[29] Sidani S, Guruge S, Miranda J, Ford-Gilboe M, Varcoe C. Cultural Adaptation and Translation of Measures: An Integrated Method. Res Nurs Health. 2010;33:133–43.
[30] Willis GB. Cognitive Interviewing: A Tool for Improving Questionnaire Design. Thousand Oaks, CA: Sage Publications; 2005.
[31] Creswell JW, Clark Vicki LP. Designing and conducting mixed methods research. Newbury Park, CA: Sage; 2017.
[32] Antunes B, Daveson B, Ramsenthaler C, Benalia H, Lopes Ferreira P, Higginson I. The Palliative care Outcome Scale Manual for cross-cultural adaptation and psychometric validation. Cicely Saunders Institute, King’s College London. 2012. http://pos-pal.org/Resources.php. Accessed 17 Oct 2019.
[33] Kulis D, Bottomley A, Velikova G, Greimel E, Koller M. EORTC Quality of Life Group translation procedure manual. European Organization for Research and Treatment of Cancer. 2017. http://www.eortc.org/app/uploads/sites/2/2018/02/translation_ manual_2017.pdf. Accessed 17 Oct 2019.
[34] Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P, Translation ITFf, Cultural A. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8:94-104.
[35] Chavez L, Canino G. Toolkit on Translating and Adapting Instruments. Human Services Research Institute; 2005.
[36] Brod M, Tesler LE, Christensen TL. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18:1263–78.
[37] Green J, Thorogood N. Qualitative Methods for Health Research. 2nd ed. London: Sage Publications; 2009.
[38] Osborne TR, Ramsenthaler C, de Wolf-Linder S, Schey SA, Siegert RJ, Edmonds PM, Higginson IJ. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer. 2014;14:496.
[39] Velikova G, Awad N, Coles-Gale R, Wright EP, Brown JM, Selby PJ. The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology. 2008;12:690–8.
[40] Bausewein C, Fegg M, Radbruch L, Nauck F, von Mackensen S, Borasio GD, Higginson IJ. Validation and clinical application of the German version of the palliative care outcome scale. J Pain Symptom Manage. 2005;30:51-62.
[41] Koller M, Kantzer V, Mear I, Zarzar K, Martin M, Greimel E, Bottomley A, Arnott M, Kuliś D; ISOQOL TCA-SIG. The process of reconciliation: evaluation of guidelines for translating quality-of-life questionnaires. Expert Rev Pharmacoecon Outcomes Res. 2012;12:189-97.
[42] Willis GB, Royston P, Bercini D. The use of verbal report methods in the development and testing of survey questionnaires. Appl Cogn Psychol. 1991;5:251-67.
[43] Lee J. Conducting Cognitive Interviews in Cross-National Settings. Assessment. 2014;21:227-40.
[44] Tourangeau R. Cognitive sciences and survey methods. In: Jabine TB, editor. Cognitive aspects of survey methodology: building a bridge between disciplines. Washington, DC: National Academy Press; 1984. p. 73-101.
[45] Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC. The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481]. BMC Palliat Care. 2005;4:7.
[46] Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.
[47] Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10:269–81.
[48] Beck I, Olsson Möller U, Malmström M, Klarare A, Samuelsson H, Lundh Hagelin C, Rasmussen B, Fürst CJ. Translation and cultural adaptation of the Integrated Palliative care Outcome Scale including cognitive interviewing with patients and staff. BMC Palliat Care. 2017;16:49.
[49] Blozik E, Scherer M, Lacruz ME, Ladwig KH; KORA study group. Diagnostic utility of a one-item question to screen for depressive disorders: results from the KORA F3 study. BMC Fam Pract. 2013;14:198.
[50] Vahter L, Kreegipuu M, Talvik T, Gross-Paju K. One question as a screening instrument for depression in people with multiple sclerosis. Clin Rehabil. 2007;21:460-4.
[51] Veronese S, Rabitti E, Costantini M, Valle A, Higginson I. Translation and cognitive testing of the Italian Integrated Palliative Outcome Scale (IPOS) among patients and healthcare professionals. PLoS One. 2019;14:e0208536.
[52] Sterie AC, Bernard M. Challenges in a six-phase process of questionnaire adaptation: findings from the French translation of the Integrated Palliative care Outcome Scale. BMC Palliat Care. 2019;18:38.
[53] Stead ML, Brown JM, Velikova G, Kaasa S, Wisløff F, Child JA, Hippe E, Hjorth M, Sezer O, Selby P. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol. 1999;104:605-11.
[54] Heinemann AW, Fisher WP, Gershon R. Improving health care quality with outcomes management. J Prosthet Orthot. 2006;18:46-50.
[55] Kaplan SH, Kravitz RL, Greenfield S. A critique of current uses of health status for the assessment of treatment effectiveness and quality of care. Med Care. 2000;38:184-91.
[56] Ferrell B, Grant M, Schmidt GM, Rhiner M, Whitehead C, Fonbuena P, Forman SJ. The meaning of quality of life for bone marrow transplant survivors. Part 1. The impact of bone marrow transplant on quality of life. Cancer Nurs. 1992;15:153-60.
[57] Dahan JF, Auerbach CF. A qualitative study of the trauma and posttraumatic growth of multiple myeloma patients treated with peripheral blood stem cell transplant. Palliat Support Care. 2006;4:365-87.
[58] Parsons JA, Greenspan NR, Baker NA, McKillop C, Hicks LK, Chan O. Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study. BMC Cancer. 2019; 19(1):264.
[59] Carlson LE. Screening alone is not enough: the importance of appropriate triage, referral, and evidence-based treatment of distress and common problems. J Clin Oncol. 2013;31:3616-7.
[60] Hollingworth W, Metcalfe C, Mancero S, Harris S, Campbell R, Biddle L, McKell-Redwood D, Brennan J. Are needs assessments cost effective in reducing distress among patients with cancer? A randomized controlled trial using the Distress Thermometer and Problem List. J Clin Oncol. 2013;31:3631-8.
[61] Dionne-Odom JN, Azuero A, Lyons KD, Hull JG, Tosteson T, Li Z, Frost J, Dragnev KH, Akyar I, Hegel MT, Bakitas MA. Benefits of Early Versus Delayed Palliative Care to Informal Family Caregivers of Patients With Advanced Cancer: Outcomes From the ENABLE III Randomized Controlled Trial. J Clin Oncol. 2015;33:1446-52.
[62] McCaughan D, Roman E, Smith AG, Garry AC, Johnson MJ, Patmore RD, Howard MR, Howell DA. Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study. Palliat Med. 2019;33:518-30.
[63] LeBlanc TW, El-Jawahri A. Hemato-oncology and palliative care teams: is it time for an integrated approach to patient care? Curr Opin Support Palliat Care. 2018;12:530-53.
[64] Porta-Sales J, Guerrero-Torrelles M, Moreno-Alonso D, Sarrà-Escarré J, Clapés-Puig V, Trelis-Navarro J, Sureda-Balarí A, Fernández De Sevilla-Ribosa A. Is Early Palliative Care Feasible in Patients With Multiple Myeloma? J Pain Symptom Manage. 2017;54:692-700.
[65] El-Jawahri A, Traeger L, Greer JA, VanDusen H, Fishman SR, LeBlanc TW, Pirl WF, Jackson VA, Telles J, Rhodes A, Li Z, Spitzer TR, McAfee S, Chen YA, Temel JS. Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial. J Clin Oncol. 2017;35:3714-21.
[66] El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, Jackson VA, Telles J, Rhodes A, Spitzer TR, McAfee S, Chen YA, Lee SS, Temel JS. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2016;316:2094-103.